Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
With
Agensys, Inc.
Cohorts of 1-6 patients will be administered AGS-1C404 in sequentially rising dose levels. Dose escalation will continue until the MTD of AGS-1C4D4 is established or the maximum planned dose is reached.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patient has hormone-refractory metastatic prostate cancer
You may not be if
Patient has had chemotherapy, radiotherapy, or biological therapy within the past 4 weeks or has not recovered from side effects
Patient is currently participating or has participated in an investigational study within the past 30 days
Patient has illness or circumstance that could limit compliance with the study requirements
Patient uses illicit drugs or had a recent history of drug or alcohol abuse within the last year
